The use of furosemide during Intravenous Immunoglobulin therapy should not always be considered contraindicated

dc.authorscopusid57193861198
dc.authorscopusid55535268200
dc.authorscopusid57224070458
dc.authorscopusid6602124655
dc.contributor.authorEFE S.
dc.contributor.authorDemircan F.
dc.contributor.authorUÇAN A.
dc.contributor.authorİNAL V.
dc.date.accessioned2024-06-12T10:25:08Z
dc.date.available2024-06-12T10:25:08Z
dc.date.issued2024
dc.description.abstractAims: Endothelial damage in acute respiratory distress syndrome (ARDS) increases capillary permeability, resulting in an increase in free lung fluid, interstitial pulmonary edema, and ventilation-perfusion imbalance. Due to their high osmolarity, Intravenous Immunoglobulin (IVIG) treatment may deepen hypoxemia by increasing lung fluid leakage. Adding furosemide to IVIG treatment in ARDS secondary to COVID-19 (CARDS) cases may increase treatment tolerance and success. Materials and methods: In our study, we aimed to measure the effectiveness of this treatment combination in CARDS cases and to report the observed complications. Patients who were followed up in the 34-bed adult COVID intensive care unit between March 2020/2021 and who received IVIG, high-dose corticosteroid, and furosemide combination therapy were included in the study. Patients' age, gender, comorbidities, Acute Physiology, and Chronic Health Assessment II (APACHE-II), and Sequential Organ Failure Assessment (SOFA) scores were recorded. The day IVIG duration of treatment, additional medical treatments, respiratory support treatments, laboratory examinations, the percentage of involvement of lung lesions (Covid Visual Assessment Scale), clinical outcomes, and treatment complications were recorded. Results: Combination therapy with found to improve respiratory failure in 50 % of patients. Troponin elevation was found in two patients, femoral artery embolism in one patient, and thrombosis in the femoral vein in one patient. In addition to IVIG treatment, the administration of two doses of immune plasma increased the chance of discharge (P = 0.037) Conclusion: In severe viral ARDS refractory to standard therapy, using furosemide in addition to IVIG therapy has an acceptable side-effect profile and may increase treatment success. Furosemide given during IVIG therapy should not be considered a contraindication in every patient. © 2023 The Author(s)en_US
dc.identifier.doi10.1016/j.medidd.2023.100171
dc.identifier.issn2590-0986
dc.identifier.scopus2-s2.0-85179077501en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1016/j.medidd.2023.100171
dc.identifier.urihttps://hdl.handle.net/20.500.14551/16173
dc.identifier.volume21en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofMedicine in Drug Discoveryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectConvalescent Plasma; Covid Ards; Furosemid; Hfnc; Ivigen_US
dc.subjectAntiserum; Dexamethasone; Furosemide; Immunoglobulin; Methylprednisolone; Troponin; Adult; Adult Respiratory Distress Syndrome; Age Distribution; Aged; Apache; Artery Embolism; Article; Assisted Ventilation; Atrial Fibrillation; Bradycardia; Clinical Outcome; Cohort Analysis; Comorbidity; Coronavirus Disease 2019; Covid Visual Assessment Scale; Drug Contraindication; Drug Dose Reduction; Drug Overdose; Drug Safety; Drug Use; Female; Femoral Arterial Embolism; Femoral Artery Embolism; Femoral Venous Thrombosis; Follow Up; Hospital Bed Capacity; Human; Immunotherapy; Intensive Care Unit; Laboratory Test; Major Clinical Study; Male; Middle Aged; Respiratory Failure; Scoring System; Septic Shock; Sequential Organ Failure Assessment Score; Sex Ratio; Therapy Effect; Treatment Duration; Vein Thrombosisen_US
dc.titleThe use of furosemide during Intravenous Immunoglobulin therapy should not always be considered contraindicateden_US
dc.typeArticleen_US

Dosyalar